tiprankstipranks

Sabra Health Care price target lowered to $20 from $21 at BofA

BofA analyst Jeffrey Spector lowered the firm’s price target on Sabra Health Care (SBRA) to $20 from $21 and keeps a Buy rating on the shares. Based on recent property tours, quarter-to-date updates and the proximity to when 2025 guidance was initiated, the firm expects “mainly beats and meets for 1Q results” and expects a good earnings season for REITs, the analyst tells investors.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue